Drugs / Dipeptiven

Trials 4 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT04560309 Jan → Oct 2021 coronary artery disorder National Cardiovascular Center Harapan Kita Hospital Indonesia Completed No outcome recorded
Phase 43 trials
Phase 4 NCT02130674 Jan 2005 → Feb 2011 traumatic brain injury University of Zurich Completed No outcome recorded
Phase 4 NCT00732849 Jun → Sep 2002 Jagiellonian University Completed No outcome recorded
Phase 4 NCT00558155 Jun 2001 → Dec 2005 gastric cancer, malignant pancreatic neoplasm Jagiellonian University Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT05140772 Comparator Jun 2020 → Dec 2021 Menoufia University Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT00647036 Comparator Jul 2009 → Dec 2011 Institute of Child Health Completed No outcome recorded
Phase not applicable1 trial
NCT05822518 Comparator Jun 2022 → Nov 2023 urinary bladder cancer Menoufia University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Dipeptiven ClinicalTrials.gov intervention name — accepted as the source's own label NCT00732849
5

NCT05822518

NCT00558155

NCT02130674

NCT00647036

NCT05140772

Known as alanyl-glutamine dipeptide “Patients suffering from severe traumatic brain injury and requiring multimodal neuromonitoring during pharmacological coma will receive alanyl-glutamine dipeptide (Dipeptiven)...” NCT02130674
Known as L-alanyl-L-glutamine dipeptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT04560309
Modality Peptide “Patients suffering from severe traumatic brain injury and requiring multimodal neuromonitoring during pharmacological coma will receive alanyl-glutamine dipeptide (Dipeptiven)...” NCT02130674
Route Intravenous Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide” NCT04560309